Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss different uses for CAR T-cell therapy, particularly a trial in which a CAR T-Cell therapy is being evaluated in MRD-positive patients treated with chemotherapy.
First Patient Set to Receive bluebird’s Approved Sickle Cell Gene Therapy, Lyfgenia
Lovo-cel was approved as Lyfgenia in December 2023.
Prime Medicine’s Gene-Edited Stem Cell Product PM359 Cleared for US Trial in Chronic Granulomatous Disease
The company anticipates that initial data from the study will be announced next year.
CGTLive®’s Weekly Rewind – May 3, 2024
Review top news and interview highlights from the week ending May 3, 2024.
ODAC Supports MRD Endpoint in Accelerated Approval for Multiple Myeloma
The ODAC unanimously voted in favor of the use of minimal residual disease negativity.
Labcorp’s Companion Diagnostic Assay for Beqvez Receives FDA Approval
Testing for the presence of neutralizing antibodies is an essential step before patients can receive Beqvez.
FDA Activity Recap: April 2024 Features New Product Approval, 2 Expanded Indication Approvals, and More
Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.